Glucose Health Inc Stock Price, News & Analysis

Glucose Health (OTC: GLUC) completed a preferred stock conversion on Dec. 23, 2025 that turned 97% of dividend-bearing preferred shares into common stock at $0.25 per share and converted the remaining accrued dividends into common stock at $0.10 per share.

Post-conversion the company reports 27,309,271 issued and outstanding common shares, a 10,524,984 share public float, and 29,509,271 fully diluted shares including 2,200,000 management warrants; the conversion eliminated dividend-bearing preferred classes and related liabilities.

Glucose Health (OTC: GLUC) appointed strategic investor Christopher J. Jemapete to its Board of Directors effective October 29, 2025. Mr. Jemapete, an early investor since 2017, holds a substantial equity stake and brings three decades of financial‑services experience from firms such as E.F. Hutton, Shearson Lehman Brothers, Fidelity, and ALPS Distributors.

He has participated in Private Placements since 2019 and helped raise over $2 million in capital. Management highlighted an established retail distribution footprint for GLUCODOWN and FIBER UP via Amazon and the two largest U.S. pharmacy chains, and emphasized the need for adequate capitalization to execute growth plans.

Glucose Health (OTC: GLUC) appointed Edmund “Ned” Burke to its Board of Directors effective Oct 27, 2025. Burke is a veteran financial executive with 40+ years at firms including Pioneer Funds and Fidelity, and served as CEO of ALPS Holdings until his June 2019 retirement.

Key highlights: Burke led ALPS revenue growth from $15 million to $225 million (2005–2019; ~19.79% CAGR), negotiated ALPS sales to Lovell Minnick Partners (2005) and DST Systems (2011), and received the 2016 NOVA Award. He also serves on multiple mutual fund boards and is noted as one of Glucose Health’s largest shareholders.

Glucose Health (OTC: GLUC) appointed veteran financial executive Edmund “Ned” Burke to its Board of Directors effective October 23, 2025. Burke brings 40+ years of financial services leadership from firms including Pioneer Funds and Fidelity, and most recently served as CEO of ALPS Distributors.

Key track record items: Burke grew ALPS AUM from $15 million to $225 million (~19.79% CAGR over ~15 years), negotiated ALPS’ sale to Lovell Minnick in 2005, and oversaw its later acquisition by DST Systems in 2011. He also serves on boards of Financial Investors Trust, Clough Funds, and Liberty All-Star Trust. Management notes Burke is one of Glucose Health’s largest shareholders and will support the company’s growth strategy.

Glucose Health (OTC: GLUC) appointed Mark Schaftlein as CEO and board member and Marc Hatch as CFO and COO, effective October 20, 2025.

A core investor group has contributed nearly $2 million in cumulative direct investments. The company reports revenues approaching $1.1 million in a recent fiscal year with gross margins above 40%. Glucose Health markets two trademarked soluble-fiber brands, GlucoDown® and Fiber Up®, with Amazon traction and placement in diabetic sections of the nation’s two largest pharmacy retailers; a recent retail expansion reportedly doubled pharmacy store count.

Other items: patent-pending soluble fiber formula, completed week-long FDA inspection (Sept 2021), and continued board transition with Murray Fleming for administrative continuity.

Glucose Health (OTC: GLUC) announced the resignation of its Chief Executive Officer and Chief Financial Officer, effective September 30, 2025. The departure was voluntary and not requested by the company. Murray Fleming, the company's sole Director, will temporarily assume both roles to maintain administrative continuity and assist in identifying new officers.

Notably, the company disclosed having limited operating capital and expressed uncertainty about its ability to continue as a going concern. The interim leadership arrangement will continue until permanent successors are appointed, the company ceases operations, or the Board takes alternative action regarding officer appointments.

Glucose Health, Inc. (OTC: GLUC) has launched a strategic media campaign across CNBC, Fox Business, and Bloomberg Television to highlight the U.S. Department of Health and Human Services' designation of dietary fiber as a "nutrient of public health concern." The campaign targets the New York City metro area to attract retail, institutional, and investment bank attention.

The company's two main brands, GlucoDown® and Fiber Up®, feature patent-pending soluble fiber formulations competing with established products like Glucerna® and Metamucil®. GlucoDown® supports balanced glucose levels, while Fiber Up® targets metabolic and digestive health. The company aims to capitalize on expected increased consumer demand following the federal designation of dietary fiber as a priority nutrient in the Dietary Guidelines for Americans, 2020-2025.

Glucose Health, Inc. (OTC: GLUC) has highlighted its long-standing commitment to using only natural colors in its GlucoDown® and Fiber Up® products, contrasting with competitors like Metamucil® who have traditionally used synthetic dyes. Since 2017, the company's products have been formulated with natural colors from vegetables like beets and carrots, avoiding artificial dyes such as Yellow 6 and Red 40.

The company emphasizes its patent-pending metabolic nutrition formulation that supports metabolic wellness, including balanced glucose and cholesterol levels. Their products contain 100% soluble dietary fiber and natural flavors, with no preservatives or fillers, positioning the company advantageously as the U.S. Department of Health and Human Services has designated dietary fiber as a nutrient of public health concern.

Glucose Health, Inc. (OTC: GLUC) highlighted the U.S. Department of Health and Human Services (HHS) and USDA's designation of dietary fiber as one of four nutrients of public health concern in their 2020-2025 Dietary Guidelines for Americans. This federal recognition validates the company's strategic focus on fiber-based nutrition products.

The company's flagship brand GlucoDown®, a dietary fiber-infused drink formulated for balanced glucose levels, competes with major brands like Glucerna® and Boost® in national pharmacy chains. Additionally, their Fiber Up® brand, utilizing a variant of their patent-pending formulation, targets digestive and gut health, competing with Metamucil®.

CEO Murray Fleming emphasized that this federal designation aligns with their core mission since 2017, positioning the company to potentially benefit from increased government funding for dietary fiber awareness campaigns and anticipated rising consumer demand.